View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Eventsco.don 과거 순이익 실적과거 기준 점검 0/6co.don 의 수입은 연평균 -15.4%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 10.7%의 비율로 증가해 왔습니다.핵심 정보-15.38%순이익 성장률1.35%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률10.68%자기자본이익률-214.21%순이익률-143.55%최근 순이익 업데이트30 Jun 2022최근 과거 실적 업데이트공시 • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.공시 • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022공시 • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.공시 • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021모든 업데이트 보기Recent updates공시 • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.공시 • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.공시 • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022공시 • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022공시 • May 02co.don AG Announces Resignation of Hans-B. Bauerfeind as Chairman of the Supervisory Board for Health ReasonsProfessor Hans-B. Bauerfeind has informed co.don AG that he is resigning from his chairmanship of the Supervisory Board for health reasons at the age of 81 and is retiring from the Supervisory Board with immediate effect. The office of Chairman of the Supervisory Board will be taken over by Mr. Thommy Stählin, long-time member of the Supervisory Board and former Deputy Chairman of the Supervisory Board.Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 321% above last closing price of €1.39. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.공시 • Feb 26co.don AG Announces Resignation of Hans-Joachim Simons as Member of the Executive Board Effective February 28, 2022In agreement with the Supervisory Board, Dr. Hans-Joachim Simons has resigned from his position as a member of the Executive Board of CO.DON AG with effect from the end of February 28, 2022, in order to pursue new professional responsibilities.Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 245% above last closing price of €1.69. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.분석 기사 • Oct 06Here's Why co.don (ETR:CNW) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Major Estimate Revision • Aug 07Consensus EPS estimates fall to -€0.29The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €11.1m to €10.0m. Losses expected to increase from -€0.21 to -€0.29. Biotechs industry in Germany expected to see average net income decline 12% next year. Consensus price target of €4.20 unchanged from last update. Share price fell 11% to €1.12 over the past week.Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 193% above last closing price of €1.44. Stock is up 15% over the past year.공시 • Jun 04co.don Ag Announces Marketing Authorisation Granted for Spherox in the United KingdomThe MHRA (Medicines and Healthcare products Regulatory Agency) has granted marketing authorisation for the autologous medicinal product Spherox marketed by CO.DON AG, thus completing the BREXIT-related transition of the medicinal product, which has already been approved throughout the EU. The regulatory authority MHRA regulates the approval of medicines, medical devices and blood components for transfusions in the UK. The re-approval process had become necessary due to the UK's withdrawal from the European Union, as the scope of the original approval only covered EU member states.Major Estimate Revision • May 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. Forecast loss of -€0.21 per share in 2021, versus previous forecasts of €0.15 per share. Revenue forecast unchanged from €11.1m at last update. Biotechs industry in Germany expected to see average net income growth of 0.4% next year. Consensus price target of €3.80 unchanged from last update. Share price rose 4.9% to €1.07 over the past week.공시 • May 22co.don AG Receives Positive Vote of Committee for Medicinal Products for Human Use of the EMACO.DON AG received the positive vote of the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) on theapproval of the application for the indication extension of the EU-wide approved medicinal product for human use "Spherox - Spheroids from human autologous matrix-associated chondrocytes" for the use in adolescents. The CHMP's assessment is the basis for the European Commission's decision on the EU-wide authorisation of the indication extension. In the past, the European Commission followed the recommendations of the CHMP in the vast majority of applications. With the expanded indication for the EU, the treatment of symptomatic articular cartilage defects of ICRS Grade III or IV of the femoral condyle and the patella of the knee with defect sizes of up to 10 cm ^ 2 is now also possible in adolescents with closed growth plates in addition to adult patients.분석 기사 • May 06Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.공시 • Apr 29co.don AG Technology Transfer Process Gets Green Light from EMAThe European Medicines Agency has authorized the new manufacturing site in Leipzig for CO.DON AG. The Leipzig site is now formally approved for the manufacture, quality control and marketing of Spherox for the EU. This means that all the official requirements set by the EMA to produce the pharmaceutical product in Leipzig and its distribution within the EU market have been met. The technology transfer process will be completed with a routine inspection by the state authority for Saxony, which The company expects to take place in summer 2021. Spherox production is planned to start in Leipzig in August/September 2021, whereby both sites will initially produce for the EU market in parallel.분석 기사 • Mar 15Will co.don (ETR:CNWK) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Feb 08Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Longco.don AG ( ETR:CNWK ) is possibly approaching a major achievement in its business, so we would like to shine some...공시 • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021분석 기사 • Jan 04co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.While it may not be enough for some shareholders, we think it is good to see the co.don AG ( ETR:CNWK ) share price up...공시 • Dec 19CO.DON AG Appoints Achim Simons to Executive BoardThe Supervisory Board of CO.DON AG has appointed Dr. Achim Simons to the Executive Board of CO.DON AG with effect from 1 January 2021. Dr. Simons was previously a surgeon.Is New 90 Day High Low • Oct 13New 90-day low: €0.95The company is down 28% from its price of €1.32 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.Is New 90 Day High Low • Sep 19New 90-day low: €0.96The company is down 23% from its price of €1.24 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.63 per share.매출 및 비용 세부 내역co.don가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XTRA:CNW 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 2210-1411031 Mar 2210-1211031 Dec 2110-911030 Sep 218-1011030 Jun 217-1110031 Mar 216-1310031 Dec 206-1410030 Sep 206-1511030 Jun 207-1611031 Mar 207-1410031 Dec 197-1310030 Sep 196-119030 Jun 196-98031 Mar 196-78031 Dec 186-68030 Sep 186-78030 Jun 186-88031 Mar 186-87031 Dec 176-77030 Sep 176-66030 Jun 176-56031 Mar 176-45031 Dec 166-45030 Sep 166-35030 Jun 166-35031 Mar 165-34031 Dec 155-340양질의 수익: CNW 은(는) 현재 수익성이 없습니다.이익 마진 증가: CNW는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CNW은 수익성이 없으며 지난 5년 동안 손실이 연평균 15.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CNW의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CNW은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(21.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CNW는 현재 수익성이 없으므로 자본 수익률이 음수(-214.21%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/12/28 14:30종가2022/09/30 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스co.don AG는 3명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Peter-Thilo HaslerSphene Capital GmbHUlrich HuwaldWarburg Research GmbHHarald HofWarburg Research GmbH
공시 • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022
Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.
공시 • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022
공시 • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022
Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
공시 • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021
공시 • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.
공시 • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022
Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.
공시 • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022
공시 • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022
공시 • May 02co.don AG Announces Resignation of Hans-B. Bauerfeind as Chairman of the Supervisory Board for Health ReasonsProfessor Hans-B. Bauerfeind has informed co.don AG that he is resigning from his chairmanship of the Supervisory Board for health reasons at the age of 81 and is retiring from the Supervisory Board with immediate effect. The office of Chairman of the Supervisory Board will be taken over by Mr. Thommy Stählin, long-time member of the Supervisory Board and former Deputy Chairman of the Supervisory Board.
Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 321% above last closing price of €1.39. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
공시 • Feb 26co.don AG Announces Resignation of Hans-Joachim Simons as Member of the Executive Board Effective February 28, 2022In agreement with the Supervisory Board, Dr. Hans-Joachim Simons has resigned from his position as a member of the Executive Board of CO.DON AG with effect from the end of February 28, 2022, in order to pursue new professional responsibilities.
Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 245% above last closing price of €1.69. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
분석 기사 • Oct 06Here's Why co.don (ETR:CNW) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Major Estimate Revision • Aug 07Consensus EPS estimates fall to -€0.29The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €11.1m to €10.0m. Losses expected to increase from -€0.21 to -€0.29. Biotechs industry in Germany expected to see average net income decline 12% next year. Consensus price target of €4.20 unchanged from last update. Share price fell 11% to €1.12 over the past week.
Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 193% above last closing price of €1.44. Stock is up 15% over the past year.
공시 • Jun 04co.don Ag Announces Marketing Authorisation Granted for Spherox in the United KingdomThe MHRA (Medicines and Healthcare products Regulatory Agency) has granted marketing authorisation for the autologous medicinal product Spherox marketed by CO.DON AG, thus completing the BREXIT-related transition of the medicinal product, which has already been approved throughout the EU. The regulatory authority MHRA regulates the approval of medicines, medical devices and blood components for transfusions in the UK. The re-approval process had become necessary due to the UK's withdrawal from the European Union, as the scope of the original approval only covered EU member states.
Major Estimate Revision • May 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. Forecast loss of -€0.21 per share in 2021, versus previous forecasts of €0.15 per share. Revenue forecast unchanged from €11.1m at last update. Biotechs industry in Germany expected to see average net income growth of 0.4% next year. Consensus price target of €3.80 unchanged from last update. Share price rose 4.9% to €1.07 over the past week.
공시 • May 22co.don AG Receives Positive Vote of Committee for Medicinal Products for Human Use of the EMACO.DON AG received the positive vote of the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) on theapproval of the application for the indication extension of the EU-wide approved medicinal product for human use "Spherox - Spheroids from human autologous matrix-associated chondrocytes" for the use in adolescents. The CHMP's assessment is the basis for the European Commission's decision on the EU-wide authorisation of the indication extension. In the past, the European Commission followed the recommendations of the CHMP in the vast majority of applications. With the expanded indication for the EU, the treatment of symptomatic articular cartilage defects of ICRS Grade III or IV of the femoral condyle and the patella of the knee with defect sizes of up to 10 cm ^ 2 is now also possible in adolescents with closed growth plates in addition to adult patients.
분석 기사 • May 06Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
공시 • Apr 29co.don AG Technology Transfer Process Gets Green Light from EMAThe European Medicines Agency has authorized the new manufacturing site in Leipzig for CO.DON AG. The Leipzig site is now formally approved for the manufacture, quality control and marketing of Spherox for the EU. This means that all the official requirements set by the EMA to produce the pharmaceutical product in Leipzig and its distribution within the EU market have been met. The technology transfer process will be completed with a routine inspection by the state authority for Saxony, which The company expects to take place in summer 2021. Spherox production is planned to start in Leipzig in August/September 2021, whereby both sites will initially produce for the EU market in parallel.
분석 기사 • Mar 15Will co.don (ETR:CNWK) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Feb 08Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Longco.don AG ( ETR:CNWK ) is possibly approaching a major achievement in its business, so we would like to shine some...
공시 • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021
분석 기사 • Jan 04co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.While it may not be enough for some shareholders, we think it is good to see the co.don AG ( ETR:CNWK ) share price up...
공시 • Dec 19CO.DON AG Appoints Achim Simons to Executive BoardThe Supervisory Board of CO.DON AG has appointed Dr. Achim Simons to the Executive Board of CO.DON AG with effect from 1 January 2021. Dr. Simons was previously a surgeon.
Is New 90 Day High Low • Oct 13New 90-day low: €0.95The company is down 28% from its price of €1.32 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.
Is New 90 Day High Low • Sep 19New 90-day low: €0.96The company is down 23% from its price of €1.24 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.63 per share.